Meissa Vaccines, a South San Francisco, CA-based biotechnology company developing vaccines to prevent viral respiratory infections, closed a $30m Series A financing.
Morningside Ventures made the investment. In conjunction with the deal, Isaac Cheng M.D. and Stephanie O’Brien of Morningside will join the company’s board of directors.
The company intends to use the funds to expand the team, conduct Phase 1 and 2 clinical trials for its investigational vaccine for respiratory syncytial virus (RSV), and support a viral vaccine pipeline based on its synthetic biology technology.
Led by Martin Moore, Ph.D., cofounder, and CEO, Meissa provides a technology platform that leverages synthetic biology and genetic engineering for the rational design of vaccines that solve suboptimal immune responses, vaccine stability, and manufacturing.
The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert. They are supported by a team with extensive experience in all aspects of vaccine development.
Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.